Novo Nordisk signs Nanexa deal up to $1.3B

Nanexa’s shares tore through the open in Stockholm on Friday. At 0723 GMT the stock was up 122 percent. Intraday it climbed 127 percent. Hours after the late-Thursday announcement, the morning of September 25, 2026, belonged to the Swedish firm. Volume and attention arrived together and stayed fixed on one ticker.

Novo Nordisk shares moved almost not at all on the same news, up just 0.2 percent. One small-cap chart redrew itself in a single morning. The larger partner’s tape barely registered a change.

The global exclusive licence was worth up to €1.165 billion. Converted into dollars the same ceiling stood at about $1.33 billion; in Danish kroner it reached 8.7 billion. That figure was the maximum Nanexa could receive if every milestone was met. Nanexa became eligible for €615 million, roughly $700 million, paid as an upfront sum plus development and regulatory milestone payments. A further €550 million, equal to $626 million, was linked solely to sales milestones. Low single-digit percentage royalties on any resulting product sales completed the financial terms.

The licence granted Novo Nordisk exclusive global rights for use across as many as five development programs. The Danish company assumed leadership of both global development and commercialization for all of them. The programs were directed at monthly and quarterly dosing of peptide drugs for obesity, type 2 diabetes, and other cardiometabolic diseases. Extending the time between injections was the practical aim written into every clause.

Days earlier Novo Nordisk’s Capital Markets Day left investors underwhelmed. Chief scientific officer Martin Holst Lange set out plans to take a once-monthly GLP-1 into the clinic this year and mapped the half-life and tolerability gaps. “Over the next one year, I would say, we actually expect to see at least three or four first human doses with once-monthly GLP-1, because I cannot promise you, obviously, that the first will be the best.” He said the company needed to fully understand the half-life of its candidates; half-lives from others were not necessarily lending themselves fully to a once-monthly therapy. On the rival once-monthly data already in view the assessments were direct. “I'm not sure that the data were as compelling as we had hoped for, in particular, on the tolerability side, but also a little bit on the efficacy side.” Titration had become part of the same shortfall. “They really had to think about their titration because the once-monthly tolerability was not as attractive as I would have expected.” “To give patients something in a once-monthly setting, the proposition has to be that it is a very attractive tolerability profile.” That was the bar a monthly product still had to clear.

PharmaShell works on the particle itself. Atomic layer deposition lays an ultra-thin inorganic coating onto each individual drug particle. Once injected, those coated particles form depots at the injection site. As the coating dissolves, the drug particles enter the bloodstream. The shell, not the bare molecule, sets the pace of release and turns a single shot into a controlled depot.

David Westberg placed the Novo licence against the platform’s earlier external test. “Following our licence and option agreement with mRNA vaccine specialist Moderna in 2025 this agreement further strengthens the external validation of PharmaShell as a broadly application drug delivery platform.” The 2025 Moderna licence and option agreement had already moved PharmaShell beyond a single company’s walls. An mRNA vaccine specialist had licensed and optioned the same coating, treating it as a delivery platform rather than a one-off formulation. The Novo agreement added the second stamp, attaching the particle-level shell to peptide drugs that still required longer intervals between doses than the molecules themselves could supply.

Novo Nordisk could now point PharmaShell at as many as five peptide programs. The exclusive licence placed the full weight of execution on the Danish side. Nanexa would collect when development milestones were hit, when regulatory milestones were cleared, and when sales milestones later activated. The royalties would then run for as long as the products remained on the market. A company whose roots reached back to insulin work in the 1920s now held a particle-level tool for stretching the dosing of related medicines. The same franchise that had grown into Europe’s highest-valued company now had five new slots for the coating.

On the Friday tape the market had already assigned the new value. Nanexa traded to 15.50 SEK from a prior close of 5.93 SEK. Reuters called it the highest level in over five years.